ARS Pharmaceuticals, Inc. (SPRY)
9.42
+0.43
(+4.78%)
USD |
NASDAQ |
Jun 09, 16:00
9.42
0.00 (0.00%)
After-Hours: 20:00
ARS Pharmaceuticals SG&A Expense (Quarterly) : 72.20M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 12.03M |
| Heron Therapeutics, Inc. | 26.45M |
| ACADIA Pharmaceuticals, Inc. | 171.02M |
| Alnylam Pharmaceuticals, Inc. | 322.55M |
| Savara, Inc. | 15.57M |